PT-141 research: desire, distress and the RECONNECT trials
The pivotal studies answered a precise question. The interesting argument starts with how much the answers changed.
The RECONNECT population
PT-141 research has a substantial human trial record. Two identical Phase 3 randomized, placebo-controlled trials enrolled 1,267 premenopausal women with HSDD and compared 1.75 mg subcutaneous bremelanotide, used as needed, with placebo over 24 weeks. Subcutaneous means under the skin. Both trials met both primary outcomes.
That is a firmer starting point than the molecule's reputation alone. I give the program credit for asking about desire and the distress associated with low desire in a defined population. Those are recognisable human concerns, even when their measurement needs a questionnaire.
PT-141 benefits: the measured changes
The integrated desire-domain result on the Female Sexual Function Index was +0.35 versus placebo (P < .001). On item 13 of the Female Sexual Distress Scale–Desire/Arousal/Orgasm, which concerns distress about low desire, the integrated difference was -0.33 (P < .001).
The two numbers come from different measures. Adding them together, or reading them as percentages, would change their meaning. They describe average differences from placebo on questionnaire scores. My opinion: the modest size deserves as much room in the discussion as the successful statistical test. I can take distress seriously without inflating an average improvement.
The record includes criticism of the clinical meaningfulness of these outcomes. An expert evaluation of bremelanotide weighs efficacy, safety and its place in therapy. Trial-scale changes still leave the connection to individually valued improvement unresolved. The averages alone cannot settle that.
The 52-week extension
The open-label extension enrolled 684 women and followed as-needed use for up to 52 weeks. Sexual-desire improvements were sustained and no new safety signals emerged. Nausea occurred in 40.4%, flushing in 20.6% and headache in 12.0% as drug-related treatment-emergent events.
Open-label means the treatment was known. The extension persuades me that longer exposure deserves examination, though it serves a different purpose from the blinded comparison. Sustained improvement among extension participants adds to the picture; nausea, the principal tolerability issue, also helps explain why staying with treatment can be difficult. The side-effect chart shows those event frequencies together.
Specialised PT-141 research: brain imaging
In a randomized, double-blind crossover fMRI study of 31 premenopausal women with HSDD, MC4R agonism increased sexual desire for up to 24 hours and altered responses to erotic stimuli. Functional MRI tracks changes associated with brain activity; the reported findings included greater amygdala-insula connectivity and cerebellar/supplementary-motor activity.
I appreciate the attempt to connect a subjective experience with brain processing. A scanner still cannot supply the missing personal answer to “was the change worthwhile?” The mechanism page follows the central-signaling question further.
PT-141 laboratory research
In female rats, PT-141 increased sexual solicitation without changing reflexive responses or general movement. A 2025 study in female Syrian hamsters found melanocortin-receptor mRNA concentrated in ventral-tegmental-area dopamine neurons, yet bremelanotide neither changed that mRNA nor enhanced sexual reward in a place-preference test.
These animal findings concern different aspects of sexual behaviour. The hamster result makes me resist a tidy claim that more desire simply means more reward through every dopamine circuit. It narrows a mechanistic question; it supplies no new human treatment indication.
Is PT-141 FDA-approved?
Bremelanotide injection received FDA approval on June 21, 2019, under NDA 210557 for acquired, generalized HSDD in premenopausal women. Approval excludes men, postmenopausal women, erectile dysfunction and enhancement of sexual performance. Other uses are off-label. Material described as a PT-141 research chemical sits outside this approval and is for laboratory research only.
PT-141 is not a US controlled or scheduled substance. Melanocortin agonists fall under WADA's non-approved-substances framework (S0) in the relevant non-approved context; athletes need current WADA guidance for their circumstances.